Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
CAMBRIDGE, Mass., Dec. 08, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14, 2016, starting at 8:30 a.m. ET. This event will be available via webcast and conference call only.
During the virtual R&D Day, members of the Genocea leadership team and leading physicians will provide a comprehensive overview of lead product candidate GEN-003 for the treatment of genital herpes, which is expected to enter Phase 3 development in 2017, and share how the Company is applying its unique and proprietary T cell antigen identification platform, ATLAS™, to immuno-oncology and cancer vaccine development.
Webcast & Conference Call Information
A live webcast of the R&D Day can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
Interested participants and investors may also join the event by conference call by dialing (800) 708-4540 (domestic) or (847) 619-6397 (international) and referencing the conference ID 43927983.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
